Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Carl Diedrich Schlenkhoff"'
Autor:
W. Reifenhäuser, B. Zimmer, C. Wildenhain, Felix M. Mottaghy, Alexander Heinzel, C. Höhling, Andreas Bockisch, A. Heyll, C. Böhme, Kambiz Rahbar, Alexander Drzezga, W. Burchert, Ingo G.H. Schmidt-Wolf, Carl Diedrich Schlenkhoff, Hojjat Ahmadzadehfar, Georg Feldmann, R. Mengel, M. R. Schmidt, C. Kreuzer, D. Laufer, U. Fabry, E. Ost, Stefan C. Müller, Michael Schäfers, Martin Boegemann, H-W. Müller, Axel Heidenreich, P. Albers, Markus Dietlein, Markus Essler, Ken Herrmann
Publikováno v:
Der Urologe. 57:709-713
In the last 3 years, Lutetium-177 prostate-specific membrane antigen radioligand therapy (Lu-177-PSMA-RLT) has received increasing attention in nuclear medicine as a new form of treatment for castration-resistant metastatic prostate cancer. This ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cee2fe2df655b570ff2d5ebbeb5b5a5
https://doi.org/10.1007/s00120-018-0642-2
https://doi.org/10.1007/s00120-018-0642-2
Autor:
Florian Gaertner, Anna Yordanova, Stephan Schlolaut, Carl Diedrich Schlenkhoff, Markus Essler, Zool Hilmi Awang, Stefan Hirzebruch, Hojjat Ahmadzadehfar, Rolf Fimmers, Stefan Hauser
Publikováno v:
Oncotarget
Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis of and therapy for metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to measure overall-survival (OS) in mCRPC patients who received ei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f5872e0032635ee42964ef148292027
https://doi.org/10.18632/oncotarget.21600
https://doi.org/10.18632/oncotarget.21600
Autor:
Hojjat Ahmadzadehfar, Stefan Kürpig, Stefan Hauser, Markus Essler, Xiao Wei, Simone Wegen, Rolf Fimmers, Elisabeth Eppard, Anna Yordanova, Carl Diedrich Schlenkhoff
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 44:1448-1454
Up to 30% of patients with castration-resistant prostate cancer (CRPC) do not show any response to the first cycle of radioligand therapy (RLT) with [177Lu]Lu-PSMA-617 (Lu-PSMA). We evaluated patient response to the second and third cycles of RLT in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f578e6b88ad24858fab7f42e10015dc
https://doi.org/10.1007/s00259-017-3716-2
https://doi.org/10.1007/s00259-017-3716-2
Autor:
Rolf Fimmers, Stefan Kürpig, Elisabeth Eppard, Hojjat Ahmadzadehfar, Sebastian Rogenhofer, Markus Essler, Florian C. Gärtner, Anna Yordanova, Carl Diedrich Schlenkhoff
Publikováno v:
Oncotarget
Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer (PC), making it an optimal target for the treatment of metastasized PC. Radioligand therapy (RLT) with 177Lu-PSMA-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7f9c77c6a48ebed0b64689ca867bff5
https://doi.org/10.18632/oncotarget.7245
https://doi.org/10.18632/oncotarget.7245
Publikováno v:
Clinical nuclear medicine. 42(9)
Two castration-resistant prostate cancer patients, both with cerebral and visceral and lymphatic metastases, received multiple cycles of Lu-PSMA-617 treatments. The prognosis of both cases is dependent on brain metastases. Between Lu-PSMA-617 treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc7b9bfc8443f10517f3234ebf56ff81
https://pubmed.ncbi.nlm.nih.gov/28719450
https://pubmed.ncbi.nlm.nih.gov/28719450
Publikováno v:
Clinical nuclear medicine. 41(11)
An 81-year-old castrate-resistant prostate cancer man with multiple lymph node, bone, and hepatic metastases received four cycles of Lu-PSMA-617 treatments at our department from May to December 2015. All of his liver metastases showed PSMA expressio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97e065b0139c0c219dcf44ce083cd734
https://pubmed.ncbi.nlm.nih.gov/27607162
https://pubmed.ncbi.nlm.nih.gov/27607162
Autor:
Markus Essler, Matthias Schmidt, Florian Gaertner, Hojjat Ahmadzadehfar, Carl Diedrich Schlenkhoff
Publikováno v:
Clinical nuclear medicine. 41(6)
A 75-year-old man with castrate-resistant prostate cancer and increasing prostate-specific antigen (PSA) level developed severe bone marrow depression during Ra radionuclide therapy. Because of this, he was treated with Lu-PSMA in compassionate use f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b65e510753a4a533aa1c020c67de9068
https://pubmed.ncbi.nlm.nih.gov/26909716
https://pubmed.ncbi.nlm.nih.gov/26909716
Publikováno v:
Clinical nuclear medicine. 41(7)
An 80-year-old patient with castrate-resistant prostate cancer presented to our department for PSMA imaging because of a rising prostate-specific antigen (PSA) level. The tumor was diagnosed in 2004. GnRh analog was the only treatment the patient rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b96a389a2573210ea991e34772409342
https://pubmed.ncbi.nlm.nih.gov/26909718
https://pubmed.ncbi.nlm.nih.gov/26909718
Autor:
Hojjat Ahmadzadehfar, Markus Essler, Florian Gaertner, Stefan Hauser, Carl Diedrich Schlenkhoff
Publikováno v:
Clinical nuclear medicine. 41(5)
Prostate cancer was diagnosed in a 71-year-old man with an elevated prostate-specific antigen. The CT of the abdomen showed multiple para-aortal lymph nodes, and thus, a Ga anti-prostate-specific membrane antigen (PSMA-11) PET/CT was initiated, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64ac4fb71fa747435b331ae13b5b9074
https://pubmed.ncbi.nlm.nih.gov/26859213
https://pubmed.ncbi.nlm.nih.gov/26859213
Publikováno v:
Clinical Nuclear Medicine. 42:639-640
A rare accident of a subcutaneous extravasation in the elbow with 4280 MBq Lu-PSMA-617 occurred in our clinic. We tried to reduce the damage by warming the elbow for 12 hours, then cooling it, and recommended the patient avoid exercises with the elbo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0de5ec2bc4edd3131085955edcc69761
https://doi.org/10.1097/rlu.0000000000001715
https://doi.org/10.1097/rlu.0000000000001715